Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

ANI Pharmaceuticals, Inc. Acquires State-of-the-Art Rx Facilities and Inks Long-Term Supply Agreement with Solvay Pharmaceuticals

By Pharmaceutical Processing | May 9, 2007

ANI Pharmaceuticals has announced a major expansion of its Rx capabilities with the acquisition from Solvay Pharmaceuticals, Inc. of two manufacturing facilities located in Baudette, MN. The plants add 173,000 sq. ft. of manufacturing and laboratory capacity, substantially expanding ANI’s capabilities and enhancing its rapid growth. The facilities, both of which are fully-cGMP qualified, increase ANI’s capacity in Rx liquid and solid dose production, including products requiring containment. In addition, the state-of-the-art analytical and stability laboratories increase ANI’s research and development capabilities nearly three-fold.

Under the terms of the acquisition effective April 30, 2007, ANI will continue to supply Rx products and services to Solvay Pharmaceuticals, and other contract manufacturing customers.

“This transaction represents a defining event for ANI, providing expanded liquid and tablet production capabilities, and a highly experienced team of individuals, which will accelerate ANI’s penetration of the Generic Prescription Market,” said Tom Anderson, President and CEO, ANI Pharmaceuticals. “We are also excited about the prospects of supporting Solvay Pharmaceuticals’ continued growth, and future expansion of this partnership between our two companies.”

“The contributions of the people who work in Baudette to Solvay Pharmaceuticals’ success can not be overstated,” said Laurence Downey, M.D., President and CEO, Solvay Pharmaceuticals, Inc. “We look forward to continuing our relationship with this talented group of people as we transition ownership to our new partners at ANI.”

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE